Interactions between CXCL12 and its receptors CXCR4 or CXCR7 are involved in tumor growth and metastasis in various types of human cancer. However, CXCL12 expression and its role in lung cancer are not fully elucidated. Here we examined the expression of CXCL12 in 54 lung cancer cell lines consisting of 23 small cell lung cancers (SCLCs) and 31 non-small cell lung cancers (NSCLCs). CXCL12 was overexpressed in lung cancer cell lines compared to non-malignant human bronchial epithelial cell lines (N = 6). CXCL12 expression was positively but weakly correlated with the expression of CXCR4 or CXCR7. We also examined CXCL12 expression in 89 NSCLC specimens and found that CXCL12 expression was significantly higher in tumor specimens from female patients, non-smokers and adenocarcinoma patients. Small interfering RNAs targeting CXCL12 inhibited cellular proliferation, colony formation and migration of CXCLl2-overexpressing lung cancer cells; however, this inhibition did not occur in lung cancer cells that lacked CXCL12. Furthermore, the anti-CXCL12 neutralizing antibody mediated inhibitory effects in three lung cancer cell lines that overexpressed CXCLI2, but not in two CXCL12 non-expressing lung cancer cell lines nor two non-malignant bronchial epithelial cell lines. The present study demonstrates that: CXCL12 is concomitantly overexpressed with CXCR4 or CXCR7 in lung cancers; CXCL12 is highly expressed in NSCLCs from females, non-smokers and adenocarcinoma patients; and disruption of CXCL12 inhibits the growth and migration of lung cancer cells. Our findings indicate that CXCL12 is required for tumor growth and provide a rationale for the anti-CXCL12 treatment strategy in lung cancer.
(8-14kDa) polypeptide signaling molecules, bind to and activate seven-transmembrane G-proteincoupled chemokine receptors (3) . Chemokines are expressed by many tumor types and play an important role in the autocrine or paracrine regulation of tumor growth and metastasis (4) . Chemokine (C-X-C motif) ligand 12 (CXCLl2)/stromal cell-derived factor I (SDF-I), a IO-kDa secreted protein, is a homeostatic chemokine that signals through chemokine (C-X-C motif) receptor 4 (CXCR4), a G protein-coupled receptor, which in turn plays a role in hematopoiesis, development, and organization of the immune system (5) . Interaction between CXCL12 and CXCR4 is involved in cell proliferation, migration, adhesion and angiogenesis in human cancers of the breast, lung, ovary and pancreas and neuroblastoma, hepatic cell carcinoma and malignant mesothelioma (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Recently, CXCR7/RDC I was the second receptor for CXCL 12 (16) to be identified, and it may function in regulating tumor growth (17) (18) . However, the expression of CXCL 12 and its role in the development of lung cancer have not been fully elucidated.
In the present study, we demonstrated that CXCL 12 was overexpressed in lung cancer cell lines as compared to non-malignant bronchial epithelial cells and the expression was positively but weakly correlated with the expression of CXCR4 or CXCR7, suggesting the concomitant expression of CXCLl2 with CXCR4 or CXCR7. A clinicopathological analysis of the CXCLI2 expression in primary NSCLC tumor specimens revealed that CXCL 12 was highly expressed in NSCLCs from female patients, non-smokers and adenocarcinoma patients. Disruption of CXCL 12 mediated by small interfering RNAs (siRNAs) or an anti-CXCL 12 neutralizing antibody inhibited the in vitro growth and migration of CXCL 12overexpressing lung cancer cells. These results indicate that CXCL 12 is required for tumor growth and that the anti-CXCL 12 treatment strategy could be effective for lung cancer.
MATERIALS AND METHODS

Cell lines and specimens
We used 23 SCLC cell lines (NCI-H 187, -H209, -H345, -H378, -H524, -H526, -H740, -H865, -H889, -H 1045, -H I092, -H 1184, -H 1238, -H 1339, -H 1607, -H 1618, -HI672, -H 1963, -H2141, -H2171, -H2227, HCC33 and N417) and 31 NSCLC cell lines (NCI-H23, -HI57, -H322, -H358, -H441, -H460, -H520, -H661, -H838, -HI264, -HI299, -HI395, -HI437,-H1648, -HI666, -HI792, -HI819, -H2009, -H2077, -H2087, -H2122, -H2126, -H3255, HCCI5, HCC44, HCC78, HCC95, HCCI93, HCC515, HCC827 and A427) that were obtained from ATCC or the Hamon Center collection (University of Texas Southwestern Medical Center) (19) . Normal human bronchial epithelial cells (NHBE), small-airway epithelial (SAEC) cells and immortalized human bronchial epithelial cells (BEAS-2B, HBECl, HBEC3 and HBEC4) were used as non-tumor lung controls. NHBE and SAEC were obtained from Clonetics (San Diego, CA), and BEAS-2B was obtained from ATCC. We previously generated the HBECl, HBEC3, and HBEC4 cell lines (20) . Cancer cells were cultured in RPMI 1640 with 5% fetal bovine serum, and human bronchial epithelial cells were cultured in Keratinocyte-SFM (Invitrogen, Carlsbad, CA) medium containing 25 ug/rnl. bovine pituitary extract (Invitrogen) and 5 ng/mL epidermal growth factor (Invitrogen).
Tumors were obtained from 89 patients (45 men and 44 women) with primary NSCLC cancer who underwent surgery between July 2003 and May 2008 at the Gunma University School of Medicine Hospital (Gunma, Japan). A history of cigarette smoking was obtained from patient interviews, and non-smokers were defined as patients who had smoked < I00 cigarettes during their lifetime. Of 89 patients, 48 were smokers and 41 were nonsmokers. Tumors were histologically classified as adenocarcinomas (N = 77) or squamous cell carcinomas (N = 12), according to the criteria of the World Health Organization. We classified the postsurgical pathologic stage as stage I in 57 tumors (lA, 38; lB, 19) , stage II in 11 tumors (lIA, 6; lIB, 5) and stage III/IV in 21 tumors (lIlA, 16; IIIB, 4; IV, 1), according to the current tumor-nodemetastasis classification. Normal lung specimens (N = 8) obtained from 8 patients were used as normal controls. The study protocol was approved by the institutional review board. The specimens were immediately frozen after collection and kept at -80°C until mRNA extraction was performed. .. . . . .
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Quantitative real-time RT-PCR
The expression of the CXCLl2, CXCR4 and CXCR7 genes was examined by quantitative realtime RT-PCR as previously described (21) . Briefly, total RNA was extracted by using the RNeasy mini kit (Qiagen, Valencia, CA), and cDNA was synthesized by using 2 ug of total RNA with the SuperScript II First-Strand Synthesis using oligo (dT) primer system (Invitrogen) according to the manufacturer's instructions. Primers and probes for CXCLl2 (Assay 10: HsOO 171022 m 1), CXCR4 (Assay 10: Hs00237052_m1) and CXCR7 (Assay 10: Hs00604567_m 1) were purchased from Applied Biosystems (Tokyo, Japan). For the quantitative analysis, the TBP gene was used as an internal reference gene to normalize input cDNA as described (21) . PCR was performed in a reaction volume of 20 ul, including 2 ul of cDNA by using the Gene Amp 7700 Sequence Detection System and software (Applied Biosystems). The comparative Ct method was used to compute relative expression values.
Immunohistochemical analysis
Tumor specimens were stained with an anti-CXCL 12 mouse monoclonal antibody (MAB 350 R&D systems Inc, MN, USA) using 4 11m sections cut from paraffin blocks. Sections were incubated with the primary antibody targeting CXCLl2 overnight at 4°C. After washing with PBS, the sections were incubated with the secondary antibody, a biotinylated anti-mouse antibody from the Vecstain® ABC kit (Vector Laboratories, CA, USA), and color was developed according to the manufacturer's instructions.
Preparation and transfection of synthetic small interfering RNA (siRNA)
Two siRNAs that target different sites on CXCLl2 mRNA were purchased from Dharmacon Inc (Lafayette, CO). A siRNA against Tax (the human leukemia virus gene) was used as a negative control (22) . siRNAs were transfected into cells by using Oligofectamine transfection reagent (Invitrogen), according to a previously described method (22) . After 72 h, the cells were harvested for further analysis.
MTTassay
Cell viability was measured by using the 3-(4,5 d imethy Ith iazo 1-2y I)-2 ,5-di pheny 1-tetrazo Iium bromide (MTT) Cell Growth Assay Kit (Chemicon International, Temecula, CA), according to the manufacturer's protocol. Twenty-four hours after transfection with siRNAs or treatment with antibody, trypan blue-negative viable cells were re-plated and cultured in 96-well plates in replicates of 8. After 72 h, cells were then incubated with 0.5 mg/ml MTT for 4 h at 3TC. After MTT withdrawal, the resulting blue formazan cristae were solubilized, and absorbance was read at 570/630 nm with a microtiter plate reader. For the CXCL 12 neutralizing assay, cells were treated with 10 ug/rnl of the antihuman CXCLI2/SDF-I antibody (R&D Systems, Minneapolis, MN) or 10 ug/rnl of the IgG I isotype control antibody (R&D Systems), and the MTT assay was performed after 72 h.
Colony formation assay
The in vitro growth characteristics were tested by a colony formation assay (22) . Briefly, after 48 h of . . , . . .
Fig. 3. Comparisons of CXCLl2 expression between (A) NSCLC tumor specimens and normal lung specimens, (B) specimens from men and women, (C) and specimens from smokers and non-smokers, (D) adenocarcinomas and squamous cell carcinomas, and (E) adenocarcinoma specimens with and without EGFR mutations. Lines indicate the means ofCXCLl2 expression.
siRNA transfection or treatment with antibodies, cells were harvested, and 1000 trypan blue-negative viable cells were re-plated in each well of 6-well plates. The cells were cultured in RPMI 1640 supplemented with 5% serum, and surviving colonies were counted 14 days later after staining with methylene blue.
Migration assay
Cell migration was measured in a modified Boyden chamber, as previously described (23) . Briefly, polycarbonate filters with 8 urn pores (Neuroprobe, Gaithersburg, MD) were coated with 100 ug/rnl of collagen (Elastin Products Company, Owensville, MO) in 0.5 M acetic acid for 16 h. The coated filter was then placed on a 12-blind-well chemotaxis chamber (Neuroprobe), and cells (10' cells in 100 III per well) were loaded into the upper wells. The cells were incubated for 15 min before being loaded. After incubation at 3TC in 5% CO 2 for 4 h, the filter was disassembled. The upper side of the filter was then scraped free of cells. The cells on the lower side of the filter were fixed with methanol and stained with a Diff-Quick staining kit (International Reagent, Kobe, Japan). The number of cells that migrated to the lower side of the filter was counted.
Statistical Analysis
An unpaired t test with Welch's correction was used for comparison between two groups, and ANOVA with Bonferroni's post-hoc test was used for comparison between ::::3 groups. The correlation was analyzed by using the non-parametric Spearman's rank test. In NSCLC tumor specimens, the Mann-Whitney test was used for comparison between two groups. Progressionfree survival time was defined as the time from tumor resection to the first observation of tumor recurrence, and overall survival time was defined as the time to death from any cause. Progression-free survival and overall survival were analyzed by the Kaplan-Meier method and were compared between groups by the logrank test. Statistical analysis was performed by using the GraphPad Prism version 5.0 software program for Windows (GraphPad Software, San Diego, CA). Probability values less than 0.05 were considered statistically significant.
RESULTS
Expression ofCXCL12, CXCR4 and CXCR7 in lung cancer cell lines
The expression of CXCL12, CXCR4 and CXCR7 (Fig. 18 ) were significantly higher in lung cancer cells than in non-malignant bronchial epithelial cells (P<O.Ol for CXCLl2, and P<O.OOOI for CXCR4). In 41% of lung cancer cell lines (22 of 54 lines), CXCR7 expression levels were higher than the mean levels of the non-tumor controls, however, the difference was not statistically significant (Fig. lC) . The CXCR4 expression level was significantly higher in SCLCs than NSCLCs (Fig. IE; P<O.OOI) , whereas there was no significant difference in the expression of CXCLl2 (Fig. lD) or CXCR7 (Fig. IF) between SCLCs and NSCLCs. Thus, CXCLl2, CXCR4 and CXCR7 were overexpressed in lung cancer cell lines, and CXCR4 expression was relatively abundant in SCLCs as compared to NSCLCs. We next analyzed the correlation between CXCLl2 and CXCR4 or CXCR7 expression. CXCLl2 expression was significantly but weakly correlated with the expression of CXCR4 ( Fig. 2A ; r = 0.3002, P<0.05) and CXCR7 ( Fig. 2B ; r = 0.3333, P<0.05), suggesting that CXCL 12 was concomitantly expressed with its receptors CXCR4 or CXCR7. On the other hand, there was no statistically significant correlation between the expression of CXCR4 and CXCR7 (data not shown).
Clinicopathological significance of CXCL12 expression in NSCLC
Since clinicopathological significance of CXCL12 remains unknown, we analyzed the relationship between CXCL12 expression and clinicopathological features in 89 NSCLC tumor specimens. The CXCL12 expression levels were significantly higher in the tumor specimens than in the normal lung specimens (Fig. 3A; P<O.OOOI) . The CXCL12 expression level was significantly higher in the tumor specimens from female patients (P<0.05; Fig. 3B ), non-smokers (P<0.05; Fig. 3C ) and patients with adenocarcinoma histology (P = 0.001; Fig. 3D ), whereas there was no significant difference in the CXCL12 expression levels when groups were classified according to patient age or pathological stage (data not shown). Since EGFR mutations were frequently found in NSCLCs arising from female patients, non-smokers and adenocarcinoma patients (24) , in whom CXCL12 was highly expressed, we also assessed whether CXCL12 was highly expressed in EGFR mutationpositive tumors. In general, there are few squamous cell carcinomas of the lung which have EGFR mutations, so that it would seem to be histologically biased if the 89 patients were divided into groups with or without EGFR. Therefore, we compared the CXCL12 expression between the specimens with EGFR mutations (N = 34) and those with wildtype EGFR (N = 43) within the adenocarcinoma population. There was a tendency for higher CXCL12 expression in adenocarcinomas with EGFR mutations, although the difference did not reach statistically significant (Fig. 3E ).
Fig. 6. A) An anti-CXCLl2 neutralizing antibody inhibited cellular proliferation and migration in CXCLl2overexpressing lung cancer cell lines (HCC95, HI264 and H661) but not in non-malignant bronchial epithelial cell lines (HBEC3 and HBEC4) and lung cancer cell lines (H1299 and H2009) lacking CXCLl2 expression. Cells were treated with the CXCLl2 antibody (lO ug/ml) or the IgG1 control antibody (lO ug/ml) for 72 h and cellular proliferation was evaluated by MTT assay. B) As for the colony formation assay, cells were treated with the
We verified whether expression of CXCL12 mRNA in tumor specimens reflects on CXCL12 protein expression. CXCL12 was strongly expressed in the cytoplasm of the tumor cells which express high levels of CXCL12 mRNA; the expressions of CXCL12 mRNA are 105.5 a.u. and 153.6 a.u. for the tumors in Fig. 4A and 4B , respectively, while fibroblasts surrounding the tumors showed very weak CXCL12 expression. In contrast, CXCL12 protein expressions were undetectable or very weak in NSCLC specimens ( Fig. 4C and 4D) , in which the expressions of CXCL12 mRNA are 0.0 a.u. and 0.8 a.u. in Fig. 4C and 4D , respectively.
To assess the prognostic significance ofCXCL12 expression in NSCLC, we analyzed the difference in disease-free survival and overall survival between stage 1111 NSCLC patients (N = 68) with high CXCL12 expression and those with low CXCL12 expression. The patients were divided into two groups basedon the median level ofCXCL12 mRNA expression. There were no significant differences in survival between these groups. Thus, it is unlikely that CXCL12 expression would have significant impact on survival for NSCLC patients.
siRNA-mediated silencing of CXCL12 expression inhibited the in vitro cell growth and migration of lung cancer cells
To assess the therapeutic significance ofCXCL12 in lung cancer, we examined the effect of small interfering RNAs (siRNAs)-mediated CXCL12 gene silencing on the in vitro growth of CXCL12overexpressing lung cancer cell lines. We used the HCC95 cell line, since this line expressed the highest level of CXCL12, which was 557-fold higher than the average of CXCL12 levels in non-malignant bronchial epithelial cells (N = 6). Two siRNAs targeting different sites of CXCL12 mRNA were used to verify that the effect of siRNA-mediated knockdown of CXCL12 expression is specific. CXCL12 siRNAs were transfected into HCC95 cells, and the effect on gene silencing was monitored by real-time RT-PCR. siRNAs against CXCL12 led to marked reductions of CXCL12 mRNA expression at 72 h post-transfection, as compared to untreated cells (Fig. 5A , P<O.OOl); both siRNAs gave similar results. On the other hand, treatment with Oligofectamine or Tax siRNA did not significantly affect the CXCL12 expression levels (Fig. 5A) .
The effect of CXCL12 knockdown on cellular proliferation of HCC95 cells was then examined by an MTT assay. Knockdown of CXCL12 expression resulted in the significant inhibition of cellular proliferation in HCC95 cells (P<O.OOl) but not in the H1299 cells that lacked CXCL12 expression, whereas the treatment with Oligofectamine or Tax siRNA did not affect the cellular proliferation in any cell lines (Fig. 5B ). Furthermore, siRNA-mediated knockdown of CXCL12 significantly inhibited colony formation in HCC95 cells but not in H1299 cells (P<O.OOl; Fig. 5C ).
We also examined the effect of siRNA-mediated CXCL12 knockdown on cell migration in HCC95 cells. CXCL12 knockdown resulted in a significant attenuation in the cell migration of HCC95 cells (P<O.OOl) but not H1299 cells, whereas the treatment with Oligofectamine or Tax siRNA did not affect cell migration (Fig. 5D ). These results indicate that CXCL12 expression is required for cell growth and migration in lung cancer cells which have high expression levels of CXCL12.
Neutralization of CXCL12 by an anti-CXCL12 antibody led to inhibition ofgrowth and migration of CXCL12-overexpressing lung cancer cells
To further evaluate the inhibitory effects of CXCL12 silencing on cell growth and migration by a different approach, we tested whether treatment with an anti-CXCL12 neutralizing antibody inhibited cell growth and migration in HCC95, H1264 and H66l cell lines; these three cell lines expressed CXCL12 at the highest levels among all lung cancer cell lines used in this study. The treatment with an anti-CXCL12 antibody but not a control antibody significantly inhibited cellular proliferation in all cell lines (P<O.OOI for all lines; Fig. 6A ), but not in H1299 and H2009 lung cancer cell lines, where CXCL12 expression was undetectable, nor HBEC3 and HBEC4 nonmalignant bronchial epithelial cell lines (Fig. 6A) . Similarly, the treatment with an anti-CXCL12 antibody significantly inhibited colony formation in the three CXCL12-overexpressing lines (P<O.OOI for all lines; Fig. 6B ) but not in the CXCL12 nonexpressing cancer cell lines nor the non-malignant cell lines (Fig. 6B) . The effect of the anti-CXCL12 antibody on cell migration was further examined. Treatment with the CXCL12 antibody but not with the control antibody resulted in significant inhibition of cell migration in three CXCL12overexpressing cancer cell lines (P<O.OOI for all lines; Fig. 6C ). Conversely, the inhibitory effect of the anti-CXCL12 antibody was not observed for the CXCL12-nonexpressing cancer cell lines and the non-malignant cell lines (Fig. 6C) . Thus, we demonstrate that neutralization of CXCL12 by the anti-CXCL12 antibody is effective for inhibition of cell growth and migration in lung cancer cells that overexpress CXCL 12.
DISCUSSION
Since few studies have evaluated the expression of CXCL12 in lung cancers, we first examined the expression ofCXCL12 and its receptors CXCR4 and CXCR7 in a large number of lung cancer cell lines. We found that CXCL12 was overexpressed in lung cancer cell lines, and the expression was positively but weakly correlated with the expression ofCXCR4 or CXCR7. CXCL12 and CXCR4 chemokines have an autocrine role related to the growth and metastasis of human cancers (25) (26) . A newly identified CXCR7 receptor also promotes tumor development and metastasis through the interaction with CXCL12 (17, (27) (28) . The present results indicate co-expression ofCXCLI2-CXCR4/CXCR7 in lung cancer cells, suggesting that autocrine systems of CXCL12-CXCR4/CXCR7 may exist in lung cancer cells. In addition, the lack of correlation between the expression of CXCR4 and CXCR7 suggest that CXCL12 may differentially interact with CXCR4 or CXCR7, depending on the cellular context. Previous studies have found that SCLC cells express high levels of CXCR4, which mediates cellular proliferation, migration and adhesion in the tumors (29) (30) (31) . Together with our result that CXCR4 was abundantly expressed in SCLCs as compared to NSCLCs, it is likely that the CXCL12-CXCR4 interaction could be more important for the development of SCLC.
Recent studies demonstrated that NSCLC tumors expressed CXCL12 and that the CXCL12 expression was correlated with poor prognosis in adenocarcinoma patients (32) (33) . In our analysis of CXCL12 expression in NSCLC tumor specimens, CXCL12 expression was higher in NSCLCs from female patients, non-smokers and adenocarcinoma patients. Therefore, CXCLI2 seems to be implicated in tumor progression in NSCLC patients with these clinical characteristics. Of note, a recent study showed that aberrant methylation with the subsequent loss of CXCL12 expression occurred more frequently in male patients than in female patients (32) , suggesting that there are different roles for CXCL12 in NSCLC arising from male patients versus female patients.
EGFR mutations in the tyrosine kinase (TK) domain, which are associated with a favorable response to EGFR TK inhibitors, are frequently found in NSCLC patients who are females or non-smokers or who have adenocarcinomas (24) .
In this study, we observed a tendency for higher expression of CXCL12 in NSCLC tumors with EGFR mutations compared to the tumors with wildtype EGFR. Phillips et al. reported that activation of EGFR by EGF stimulation increased CXCR4 expression (34) . In addition, a recent study described that CXCL12-induced cellular proliferation was blocked by an EGFR tyrosine kinase inhibitor in ovarian cancer cells (35) . More recently, EGFR mutations were found more frequently in NSCLC patients with higher CXCR7 expression compared to those with lower CXCR7 expression (28) . These findings suggest the involvement of EGFR with the CXCL12-CXCR4/CXCR7 pathways. Since the number of tumor specimens analyzed in our study is relatively small, further studies with larger populations are needed to elucidate the possible role of oncogenic EGFR in the CXCL12-CXCR41 CXCR7 pathways.
The findings of CXCL12 overexpression in lung cancer prompted us to assess whether anti-CXCL12 treatment strategy could be effective for lung cancer. This idea is supported by the fact that neutralization ofCXCL12 by an anti-CXCL12 antibody suppressed the metastasis oflung tumors in scmmice (12) . We herein demonstrated that the disruption of CXCL12 by siRNAs or an anti-CXCL12 neutralizing antibody led to inhibition of the in vitro growth and migration of lung cancer cells. Su et al illustrated the therapeutic significance of the CXCLI2-CXCR4 chemokine pathways in lung cancer by using an anti-CXCR4 antibody to suppress tumor growth and metastasis in mouse models (36) . Together with these reports, our findings indicate that targeting CXCL12 has therapeutic potential for lung cancers. Considering the recent studies describing that CXCR7, a second CXCL12 receptor, promotes lung tumor growth (17) and is expressed in NSCLC patients with a poor prognosis (28), the anti-CXCL12 treatment strategy could also be effective for lung cancer where CXCL12-CXCR7 pathways are oncogenically active.
In conclusion, we demonstrated that CXCLI2 was concomitantly overexpressed with CXCR4 or CXCR7 in lung cancers. CXCL12 was expressed at higher levels in NSCLCs from female patients, non-smokers and patients with adenocarcinomas. The blockage of CXCL12 function by siRNAs or anti-CXCL12 neutralizing antibody inhibits the in vitro growth and migration of lung cancer cells. Although further in vivo studies are needed to elucidate the effectiveness of the anti-CXCL12 strategy, our findings provide an important rationale for targeting CXCL12-CXCR4/CXCR7 pathways for lung cancer.
